THE AIM of the study was the longitudinal assessment of physical development of @entity1 treated for @entity981 ( @entity981 ) in the past. A total group of 76 @entity1 (51 @entity1 ), from whom 63 get ill before puberty, were included in the study. Therapy was managed according to BFM protocols in which central nervous system (CNS) prophylaxis was used in 27 @entity1 in dose 12 Gy, @entity1499 in dose 5 g/m(2) was used in 63 @entity1 and 1g/m(2) in 13 @entity1 . Height and body mass index expressed as standard deviation score ( @entity214 ) in the time of diagnosis (H1 @entity214 , @entity3752 @entity214 ), after intensive therapy (H2 @entity214 , BMI2 @entity214 ) and after 1.7+/-3.13 years from therapy (H3 @entity214 , BMI3 @entity214 ) were assessed. RESULTS: 1. BMI2 @entity214 values increased in relation to @entity3752 @entity214 (p=0.0000001) and BMI3 @entity214 values insignificantly decreased, but they were higher than at the time of diagnosis. 2. We affirmed increase of BMI2 @entity214 in the group of @entity1 directly after the treatment (p=0.00006) and later decrease (p=0.04), so there were no differences between @entity3752 @entity214 and BMI3 @entity214 . 3. The increase of BMI2 @entity214 in comparison with @entity3752 @entity214 (p=0.007) was kept until the treatment completed in the group of @entity1 (p=0.05 between @entity3752 @entity214 and BMI3 @entity214 ). 4. The increase and next decrease of BMI @entity214 values was observed among @entity1 who get ill before puberty. But we noticed intermittent increase of BMI @entity214 in the puberty @entity1 at the time of diagnosis. 5. We affirmed increase of BMI @entity214 after the treatment completed in the group of @entity1 treated with only cytostatics. The increase of BMI @entity214 (p=0.02) and next decrease of BMI3 @entity214 (p=0.007) was noticed in the group with CNS prophylaxis, there were no differences between @entity3752 @entity214 and BMI3 @entity214 . 6. We observed increase of BMI2 @entity214 and BMI3 @entity214 in comparison with @entity3752 @entity214 (p=0.00001 and p=0.0004) in the group treated with 5 g/m(2) methotrexate. BMI3 @entity214 values were decreased in comparison with BMI2 @entity214 (p=0.01) and @entity3752 @entity214 (p=0.006) in the group treated with 1 g/m(2) methotrexate. 7. There were no significant changes in the growth rate during the treatment and after therapy. CONCLUSIONS: 1. @entity981 treatment contributes to the increase of body mass, which is kept until therapy completed, especially in the group of @entity1 . 2. Growth rate including @entity1 with CNS prophylaxis does not submit significantly disturbances.

[The influence of age, gender and modifications of therapeutic protocols on physical development of XXXX and adolescents after completion of therapy for @entity981 ].

@entity1 :: ('9606', 'Species') :: ['children', 'girls', 'boys'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity3752 :: ('648', 'Gene') :: ['BMI1'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity214 :: ('CHEBI:8984', 'Chemical') :: ['SDS']
@entity1 :: (9606,Species) :: ['children']
